ASP Isotopes (NASDAQ:ASPI) Stock Price Down 5.3% Following Insider Selling

ASP Isotopes Inc. (NASDAQ:ASPI) shares traded down 5.3% during mid-day trading on Tuesday following insider selling activity. The company traded as low as $5.38 and last traded at $5.4050. 1,337,331 shares were traded during trading, a decline of 70% from the average session volume of 4,482,298 shares. The stock had previously closed at $5.71.

Specifically, CFO Heather Kiessling sold 80,000 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $5.80, for a total value of $464,000.00. Following the completion of the sale, the chief financial officer directly owned 732,500 shares in the company, valued at $4,248,500. This represents a 9.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Canaccord Genuity Group reiterated a “buy” rating and set a $11.00 price objective on shares of ASP Isotopes in a research report on Monday, November 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ASP Isotopes in a report on Monday, December 22nd. Loop Capital set a $15.00 price target on shares of ASP Isotopes in a research report on Monday, October 27th. Finally, Cantor Fitzgerald started coverage on shares of ASP Isotopes in a research report on Thursday, December 4th. They set an “overweight” rating and a $13.00 price objective for the company. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $13.00.

ASP Isotopes Trading Down 4.8%

The firm has a market capitalization of $602.42 million, a PE ratio of -4.17 and a beta of 3.42. The company has a current ratio of 6.14, a quick ratio of 6.10 and a debt-to-equity ratio of 1.04. The business has a fifty day moving average price of $7.31 and a two-hundred day moving average price of $8.51.

ASP Isotopes (NASDAQ:ASPI) last issued its quarterly earnings data on Wednesday, November 19th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.05). The company had revenue of $4.89 million during the quarter, compared to analysts’ expectations of $2.25 million. ASP Isotopes had a negative net margin of 1,259.12% and a negative return on equity of 190.44%. Analysts expect that ASP Isotopes Inc. will post -0.24 EPS for the current fiscal year.

Institutional Trading of ASP Isotopes

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ASPI. Rovida Advisors Inc. acquired a new position in ASP Isotopes during the second quarter worth $16,148,000. Rovida Investment Management Ltd raised its holdings in shares of ASP Isotopes by 528.6% in the 2nd quarter. Rovida Investment Management Ltd now owns 2,200,000 shares of the company’s stock valued at $16,148,000 after buying an additional 1,850,000 shares during the period. Exchange Traded Concepts LLC acquired a new position in ASP Isotopes during the 2nd quarter worth about $9,593,000. Marshall Wace LLP boosted its holdings in ASP Isotopes by 3,669.1% during the 3rd quarter. Marshall Wace LLP now owns 1,279,121 shares of the company’s stock valued at $12,305,000 after acquiring an additional 1,245,184 shares during the period. Finally, Vanguard Group Inc. grew its position in ASP Isotopes by 37.9% in the 3rd quarter. Vanguard Group Inc. now owns 4,516,763 shares of the company’s stock valued at $43,451,000 after acquiring an additional 1,241,024 shares in the last quarter. Hedge funds and other institutional investors own 16.80% of the company’s stock.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.